Assay for sensitivity of tumors to DNA-platinating chemotherapy
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsEddie Reed, Meenakshi Dabholkar
Life of this patent
Estimating the term…
Abstract
Assay of the mRNA levels of ERCC1 and XPAC, two genes whose products are involved in DNA repair, provides a method for determining the sensitivity of tumors to treatment by platinum-based chemotherapy. Tumors that are resistant to cisplatin tend to express high levels of the mRNA for ERCC1 which includes exon VIII. In some tumor types, concurrent expression of ERCC1 and XPAC mRNAs is also an indicator of cisplatin resistance.
Claims13
A method for assaying sensitivity of ovarian tumor tissue to treatment with DNA platinating agents, comprising:
- i) measuring the amount of mRNA from said ovarian tumor tissue that encodes XPAC;
- ii) measuring the amount of mRNA from said ovarian tumor tissue that encodes ERCC1;
- iii) determining the ratio of XPAC mRNA measured in step (i) to the amount of ERCC1 mRNA measured in step (ii);
- iv) comparing the ratio of XPAC mRNA to ERCC1 mRNA measured in step (iii) with the ratio found in cells that are resistant to DNA platinating agents;
- and
- v) comparing the ratio of XPAC mRNA to ERCC1 mRNA measured in step (iii) with the ratio found in cells that are sensitive to DNA platinating agents;
- wherein observing that the ratio of the amount of XPAC mRNA to the amount of ERCC1 mRNA is similar to that ratio in cells sensitive to DNA platinating agents and observing that said ratio of the amount of XPAC mRNA to the amount of ERCC1 mRNA is dissimilar to that ratio in cells resistant to DNA platinating agents results in an assessment that said ovarian tumor tissue is sensitive to treatment with DNA platinating agents.
A method for assaying the sensitivity of ovarian tumor tissue to treatment with DNA platinating agents, comprising:
- i) measuring the amount of mRNA that encodes ERCC1 including exon VIII in said ovarian tumor tissue;
- ii) comparing the amount of mRNA that encodes ERCC1 including exon VIII in said ovarian tumor tissue to the amount of said mRNA found in cells that are sensitive to DNA platinating agents;
- and
- iii) comparing the amount of mRNA that encodes ERCC1 including exon VIII to the amount of said mRNA found in cells that are resistant to DNA platinating agents;
- wherein observing that the amount of said mRNA in said ovarian tumor tissue is similar to the amount of said mRNA in cells sensitive to DNA platinating agents and observing that the amount of said mRNA is dissimilar to the amount in cells resistant to DNA platinating agents results in an assessment that said ovarian tumor tissue is sensitive to treatment with DNA platinating agents.
A method for assaying the sensitivity of a T cell to treatment with DNA platinating agents, comprising:
- i) measuring the amount of mRNA that encodes ERCC1 lacking exon VIII in said T cell;
- ii) comparing the amount of mRNA that encodes ERCC1 lacking exon VIII in said T cell to the amount of said mRNA found in cells that are sensitive to DNA platinating agents;
- and
- iii) comparing the amount of mRNA that encodes ERCC1 lacking exon VIII in said T cell to the amount of said mRNA found in cells that are resistant to DNA platinating agents;
- wherein observing that the amount of said mRNA in said T cell is similar to the amount of said mRNA in cells sensitive to DNA platinating agents and observing that the amount of said mRNA in said T cell is dissimilar to the amount in cells resistant to DNA platinating agents results in an assessment that said T cell is sensitive to treatment with DNA platinating agents.
Dependencies are inferred from the claim text.